KDR and non-small cell lung carcinoma: Given the biologic rationale for combining EGFR and VEGFR targeted agents and the encouraging results from previous studies, further exploration to evaluate the effectiveness of EGFR-TKIs in combination with antiangiogenic agents as first-line therapy in EGFR-mutation-positive NSCLC patients is merited.